1,541.70
-51.60
(-3.24%)
At close: January 10 at 3:29:56 PM GMT+5:30
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
121,000,970.00
116,354,560.00
114,319,380.00
121,741,980.00
108,060,260.00
Cost of Revenue
46,736,200.00
48,790,420.00
45,866,050.00
47,781,710.00
39,966,250.00
Gross Profit
74,264,770.00
67,564,140.00
68,453,330.00
73,960,270.00
68,094,010.00
Operating Expense
64,594,890.00
61,253,410.00
57,664,590.00
55,559,790.00
50,933,650.00
Operating Income
9,669,880.00
6,310,730.00
10,788,740.00
18,400,480.00
17,160,360.00
Net Non Operating Interest Income Expense
-3,647,880.00
-5,097,930.00
-3,420,360.00
-2,886,640.00
-3,504,660.00
Pretax Income
9,443,510.00
364,950.00
2,398,420.00
14,412,460.00
13,824,750.00
Tax Provision
19,378,570.00
18,673,450.00
3,294,030.00
4,475,970.00
4,123,870.00
Net Income Common Stockholders
-8,751,760.00
-15,016,680.00
2,972,450.00
9,417,110.00
9,700,380.00
Diluted NI Available to Com Stockholders
-8,751,760.00
-15,016,680.00
2,972,450.00
9,417,110.00
9,700,380.00
Basic EPS
-31.02
-53.22
10.53
33.37
34.38
Diluted EPS
-31.02
-53.22
10.53
33.37
34.38
Basic Average Shares
282,212.03
282,170.72
282,168.16
282,168.16
282,168.16
Diluted Average Shares
282,220.05
282,178.75
282,168.16
282,168.16
282,168.16
Rent Expense Supplemental
--
626,120.00
555,990.00
353,540.00
378,990.00
Total Expenses
111,331,090.00
110,043,830.00
103,530,640.00
103,341,500.00
90,899,900.00
Net Income from Continuing & Discontinued Operation
-8,751,760.00
-15,016,680.00
2,972,450.00
9,417,110.00
9,700,380.00
Normalized Income
-6,405,767.00
-12,570,435.00
3,715,044.00
11,260,507.23
9,385,322.00
Interest Income
--
61,760.00
70,000.00
94,350.00
26,470.00
Interest Expense
3,709,640.00
5,159,690.00
3,490,360.00
2,980,990.00
3,531,130.00
Net Interest Income
-3,647,880.00
-5,097,930.00
-3,420,360.00
-2,886,640.00
-3,504,660.00
EBIT
13,153,150.00
5,524,640.00
5,888,780.00
17,393,450.00
17,355,880.00
EBITDA
18,749,570.00
11,832,740.00
12,001,460.00
22,260,600.00
21,791,420.00
Reconciled Cost of Revenue
46,736,200.00
48,790,420.00
45,866,050.00
47,781,710.00
39,966,250.00
Reconciled Depreciation
5,596,420.00
6,308,100.00
6,112,680.00
4,867,150.00
4,435,540.00
Net Income from Continuing Operation Net Minority Interest
-10,183,170.00
-18,989,960.00
-1,697,160.00
9,417,110.00
9,700,380.00
Total Unusual Items Excluding Goodwill
-5,396,290.00
-9,170,750.00
-7,731,720.00
-2,673,770.00
448,990.00
Total Unusual Items
-5,396,290.00
-9,170,750.00
-7,731,720.00
-2,673,770.00
448,990.00
Normalized EBITDA
24,145,860.00
21,003,490.00
19,733,180.00
24,934,370.00
21,342,430.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-1,618,887.00
-2,751,225.00
-2,319,516.00
-830,372.77
133,932.00
3/31/2021 - 7/1/2002
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
ZYDUSLIFE.NS Zydus Lifesciences Limited
1,004.40
-0.60%
JBCHEPHARM.NS J. B. Chemicals & Pharmaceuticals Limited
1,823.05
-2.53%
SUNPHARMA.NS Sun Pharmaceutical Industries Limited
1,784.80
-2.28%
AJANTPHARM.NS Ajanta Pharma Limited
2,834.20
-3.44%
SUVENPHAR.NS Suven Pharmaceuticals Limited
1,061.95
-3.81%
AUROPHARMA.NS Aurobindo Pharma Limited
1,199.55
-3.91%
LUPIN.NS Lupin Limited
2,191.10
-2.74%
ALKEM.NS Alkem Laboratories Limited
5,376.05
-1.43%
TORNTPHARM.NS Torrent Pharmaceuticals Limited
3,274.45
-1.42%
AKUMS.NS AKUMS DRUGS AND PHARMA L
618.25
+0.14%